Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.…
Did Valneva's Fall Catch You Out? What Bears Saw
Valneva (NASDAQ: VALN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 620 employees.
The shares were at 5.160 USD on 20 November 2026, down 42.0% over 52 weeks. Its 52-week range is 4.750 USD to 12.18 USD: the price is 57.6% below the high and 8.6% above the low.
Its market capitalisation is 490.86M USD.
Valneva reports return on equity of -108.5%, an operating margin of -80.4% and revenue down 27.7% year over year.
Its debt exceeds its cash by 88.71M EUR, a debt-to-equity ratio of 1.95. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 4 analysts cover the stock; their mean price target of 12.28 USD is 137.9% above the current price. The next earnings report is expected on 17 March 2027.